We are live on ! Find out more
SCM

Squadron Capital Management Portfolio holdings

AUM $322M
This Fund
S&P 500
This Quarter Est. Return
+39.23%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$273M
AUM Growth
+$36.9M
Cap. Flow
+$3.66M
Cap. Flow %
1.34%
Top 10 Hldgs %
67.07%
Holding
52
New
19
Increased
8
Reduced
8
Closed
15
Avg Time Held Equity + Options
0.5 quarters
Top 10 Avg Time Held Equity + Options
0.7 quarters
Top 20 Avg Time Held Equity + Options
0.5 quarters
Avg Time Held Equity only
0.6 quarters
Top 10 Avg Time Held Equity only
0.7 quarters
Top 20 Avg Time Held Equity only
0.6 quarters

Top Buys

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$9.38M
2
ANL
Adlai Nortye Group ADS
ANL
+$8.46M
3
RLMD icon
Relmada Therapeutics
RLMD
+$8.4M
4
NKTR icon
Nektar Therapeutics
NKTR
+$7.12M
5
RLAY icon
Relay Therapeutics
RLAY
+$6.02M

Top Sells

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$10.3M
2
TERN
Terns Pharmaceuticals
TERN
+$7.68M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$6.55M
4
UPB
Upstream Bio Inc
UPB
+$6.26M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$4.73M

Sector Composition

Rank Sector Weight
1 Healthcare 91.59%
2 Miscellaneous 8.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CLYM
51
Climb Bio
CLYM
$632M
– –
-100,000
Closed -$400K –
UPB
52
Upstream Bio Inc
UPB
$257M
– –
-230,650
Closed -$6.26M –
1 2
3

Similar funds

SST
S Squared Technology New York $322M AUM 92.75% 1-Year Est. Return
CW
Curio Wealth Annapolis, Maryland $322M AUM 16.26% 1-Year Est. Return
WW
Westshore Wealth Newport Beach, California $322M AUM 24.46% 1-Year Est. Return
NAG
Northstar Advisory Group Northfield, New Jersey $322M AUM 36.79% 1-Year Est. Return
JGIA
Jackson Grant Investment Advisers Stamford, Connecticut $322M AUM 20.03% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $322M AUM
KF
Ketron Financial Novato, California $322M AUM
QFPS
Quantum Financial Planning Services Spokane, Washington $323M AUM 14.02% 1-Year Est. Return

Squadron Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Squadron Capital Management held 52 positions worth $273M, up 16% from $236M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Squadron Capital Management's Q1 2026 filing shows 19 new, 8 increased, 8 reduced and 15 closed positions. Its largest new stake was Zentalis Pharmaceuticals: 3,631,000 shares worth $8.5M. The largest sale was Maze Therapeutics, an estimated $10.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Miscellaneous.

  • Squadron Capital Management's largest Q1 2026 buy was Zentalis Pharmaceuticals: 3,631,000 shares worth $8.5M.
  • Squadron Capital Management added most to Relmada Therapeutics in Q1 2026, an estimated $8.4M increase.
  • Squadron Capital Management's biggest Q1 2026 reduction was Maze Therapeutics, cutting an estimated $10.3M.
  • Squadron Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $7.68M.
  • Squadron Capital Management's ten largest holdings make up 67% of its $273M portfolio in Q1 2026.
  • Squadron Capital Management opened 19 new positions and closed 15 in Q1 2026.
  • Squadron Capital Management's portfolio value rose 16% quarter-over-quarter to $273M.

Based on Squadron Capital Management's 13F filing for Q1 2026, filed 15 May 2026.